ABRAMS' CLINICAL DRUG THERAPY RATIONALES FOR NURSING PRACTICE

Abrams clinical drug therapy rationales for nursing practice 12th edition geralyn frandsen sample Chapterd1,dThedFoundationdofdPharmacology:dQualitydanddSafety 1. Adwomanddiagnoseddwithdobsessive– compulsiveddisorderdhasdbeendprescribeddorald paroxetinedhydrochloride.dWhatdisdth edexpecteddeffectdfordthisdprescription? A. Curativedeffectdondsymptoms B. Systemicdeffectdondsymptoms C. Localdeffectdondsymptoms D. Parenteraldeffectdondsymptoms ANS:ddB Rationale:dDrugsdthatdproducedsystemicdeffectsdaredtakendintodthedbody,dcirculateddthroughd the dbloodstreamdtodtheirdsitesdofdactiondindvariousdbodydtissues,danddeventuallydeliminatedd fromdth edbody.dCurativedagentsdaredgivendtodcuredaddiseasedprocess.dIndthisdcase,dparoxetined hydrochl oridedwilldcontroldthedsymptomsdbutdnotdcuredtheddisorder.dDrugsdwithdlocaldeffects,d suchdasdsunsc reendanddlocaldanesthetics,dactdmainlydatdthedsitedofdapplication.d Paroxetined hydrochloridedisdn otdadministereddparenterally.dParenteraldagentsdaredadministeredd subcutaneously,dintramuscul arly,dordintravenously. PTS: 1 REF: p.d3,dIntroduction OBJ: 1 NAT:d ClientdNeeds:dPhysiologicaldIntegrity:dPharmacologicaldanddParenteraldTherapiesd T OP: Chapter:d1:dThedFoundationdofdPharmacology:dQualitydanddSafety KEY:d IntegrateddProcess:dNursingdProcess BLM:ddCognitivedLevel:dUnderstand NOT:d MultipledChoice 2. Adclientdhasdbeendprescribeddandantibiotic.dThisdmedicationdisdadnaturallydoccurring substancedthatdhasdbeendcheGmRicAalDlyEmSoBdOifOieSd.TW.ChaOtdMisdanotherdnamedfordthisdtypedofdmedication? A. Syntheticddrug B. Semisyntheticddrug C. Biotechnologyddrug D. Prototypeddrug ANS:ddB Rationale:dSemisyntheticddrugsd(e.g.,dmanydantibiotics)darednaturallydoccurringdsubstancesd thatd havedbeendchemicallydmodified.dSyntheticddrugsdaredmoredstandardizeddindtheirdchemicald chara cteristics,dmoredconsistentdindtheirdeffects,danddlessdlikelydtodproducedallergicdreactions.d Biotechn ologyddrugsdinvolvedmanipulatingdDNAdanddRNAdanddrecombiningdgenesdintod hybriddmolecules dthatdcandbedinserteddintodlivingdorganisms.dPrototypeddrugsdaredthedfirstd drugdofdadparticulardg roupdtodbeddeveloped. PTS: 1 REF: p.d3,dDrugdSources OBJ: 1 NAT:d ClientdNeeds:dPhysiologicaldIntegrity:dPharmacologicaldanddParenteraldTherapiesd T OP: Chapter:d1:dThedFoundationdofdPharmacology:dQualitydanddSafety KEY:d IntegrateddProcess:dNursingdProcess BLM:ddCognitivedLevel:dUnderstand NOT:d MultipledChoice 3. Whichdclassificationdappliesdtodmorphine? A. Centraldnervousdsystemddepressant B. Centraldnervousdsystemdstimulant ABRAMS'dCLINICALdDRUGdTHERAPY:dRATIONALESdFORdNURSINGdPRACTICE ABRAMS'dCLINICALdDRUGdTHERAPY:dRATIONALESdFORdNURSINGdPRACTICE C. Anti-inflammatory D. Antihypertensive ANS:ddA Rationale:dDrugsdaredclassifieddaccordingdtodtheirdeffectsdondparticulardbodydsystems,dtheird ther apeuticduses,danddtheirdchemicaldcharacteristics.dMorphinedisdclassifieddasdadcentrald nervousdsyst emddepressantdanddwilldproducedthisdeffectdindthedclient.dAdcentraldnervousd systemdstimulantdincr easesdattentiondanddraisesdmood.dAndantiinflammatorydagentddecreasesd inflammationdatdthedsitedofdtissuedordjointdinflammation.dAndantih ypertensivedagentdreducesd blooddpressure. PTS: 1 REF: p.d3,dDrugdClassificationsdanddPrototypesd OBJ: 1 NAT:d ClientdNeeds:dPhysiologicaldIntegrity:dPharmacologicaldanddParenteraldTherapiesd T OP: Chapter:d1:dThedFoundationdofdPharmacology:dQualitydanddSafety KEY:d IntegrateddProcess:dNursingdProcess BLM:ddCognitivedLevel:dRemember NOT:d MultipledChoice 4. Adclientdisdadministereddamoxicillin.dThedgenericdnamedofdthisdmedicationdbelongsdtodwhichd dru gdgroup? A. Selectivedserotonindreuptakedinhibitors B. Diuretics C. Penicillins D. ACEdinhibitors ANS:ddC Rationale:dThedgenericdnamGeR oA fteD nE iS ndB icOaOteS sdT th . eC drOugdgroupd(e.g.,ddrugsdwithdgenericdnames endingdind“cillin”daredpenicillins).dSelectivedserotonindreuptakedinhibitorsdaredmedications thatdhavedantidepressantdeffects;dSSRIdisdadbroaddclassification,dnotdadgenericdname.dDiureticsd a redmedicationsdthatdincreasedurinedoutput;ddiureticdisdadbroaddclassification,dnotdadgenericd name .dACEdinhibitordisdthedbroaddclassificationdfordthedangiotensindreceptordblockers,dnotdthed genericd name. PTS: 1 REF: p.d3,dDrugdNames OBJ: 2 NAT:d ClientdNeeds:dPhysiologicaldIntegrity:dPharmacologicaldanddParenteraldTherapiesd T OP: Chapter:d1:dThedFoundationdofdPharmacology:dQualitydanddSafety KEY:d IntegrateddProcess:dNursingdProcess BLM:ddCognitivedLevel:dUnderstand NOT:d MultipledChoice